# VEN+IDAC vs IDAC in AML

> **NCT07537257** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Guangdong Second Provincial General Hospital** · enrollment: 232 (estimated)

## Conditions studied

- AML (Acute Myelogenous Leukemia)

## Interventions

- **DRUG:** Ventoclax
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT07537257
- **Lead sponsor:** Guangdong Second Provincial General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-04-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 232 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07537257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07537257, "VEN+IDAC vs IDAC in AML". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07537257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*